ClinicalTrials.gov
public full text
Public Domain
NGR-TNF in Treating Patients With Advanced Solid Tumors
RATIONALE: Targeted therapy with tumor necrosis factor combined with a fusion protein may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of NGR-TNF in treating patients with advanced solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of GC203 TIL in Advanced Solid Tumors (NF)#1371255
- A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors#1162502
- Chemotherapy in Treating Patients With Advanced Solid Tumors#807925
- PF-03446962 in Relapsed or Refractory Urothelial Cancer#968552
- Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC#915577
Record · ID 1408378
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive